Effect of monthly minodronate after switching from raloxifene hydrochloride for the treatment of postmenopausal osteoporosis in women with loss of ovarian function due to gynecologic malignancies

Effect of monthly minodronate after switching from raloxifene hydrochloride for the treatment of postmenopausal osteoporosis in women with loss of ovarian function due to gynecologic malignancies - Effect of monthly minodronate for the treatment of osteoporosis in women with gynecologic malignancies after switching from raloxifene hydrochloride

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013916

Enrollment

Registered

2014-05-10

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Minodronate

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Female patients with osteoporosis associated with gynecologic malignancies, who gained no increase in BMD after being administered with raloxifene hydrochloride for two or more years or more

Exclusion criteria

Exclusion criteria: Patients are excluded if being 1. with concomitant use of other agents for osteoporosis 2. with concomitant use of other agents, which potentially affect bone turnover 3. with esophageal stricture or achalasia 4. unable to remain upright for 30 min after dosing 5. with hypersensitivity to minodronate or other bisphosphonates 6. with hypocalcaemia 7. with aphagia, esophagitis, gastritis, duodenitis, or ulcers 8. with severe nephropathy 9. inappropriate to participate in the study

Design outcomes

Primary

Measure	Time frame
Hip BMD or lumber BMD Bone turnover markers (serum type I collagen cross-linked N-telopeptide)	—

Countries

Japan

Contacts

Public ContactKenjiro Sawada

Osaka University Graduate School of Medicine Department of Obstetrics and Gynecology

daasawada@gyne.med.osaka-u.ac.jp06-6879-3351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026